These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33893571)

  • 1. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla
    Johnston BD; Thuras P; Porter SB; Clabots C; Johnson JR
    Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2069-2075. PubMed ID: 33893571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, bla
    Johnston BD; Thuras P; Porter SB; Clabots C; Johnsona JR
    Diagn Microbiol Infect Dis; 2021 May; 100(1):115314. PubMed ID: 33578059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
    Johnston BD; Thuras PD; Johnson JR
    Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115034. PubMed ID: 32331800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
    Johnston BD; Thuras P; Johnson JR
    PLoS One; 2018; 13(7):e0200442. PubMed ID: 29990385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Vagnone PS; Witwer M; Castanheira M; Johnson JR
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Analysis of Multidrug-Resistant Escherichia coli from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-
    Kanamori H; Parobek CM; Juliano JJ; Johnson JR; Johnston BD; Johnson TJ; Weber DJ; Rutala WA; Anderson DJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584139
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA.
    Mahoney MT; Brigman HV; Johnston BD; Johnson JR; Hirsch EB
    Am J Infect Control; 2023 Apr; 51(4):434-439. PubMed ID: 35764181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of ESBL-Producing
    Zendri F; Maciuca IE; Moon S; Jones PH; Wattret A; Jenkins R; Baxter A; Timofte D
    Microb Drug Resist; 2020 Jun; 26(6):697-708. PubMed ID: 32519936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.
    Johnson JR; Johnston B; Clabots C; Kuskowski MA; Castanheira M
    Clin Infect Dis; 2010 Aug; 51(3):286-94. PubMed ID: 20572763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe.
    Merino I; Hernández-García M; Turrientes MC; Pérez-Viso B; López-Fresneña N; Diaz-Agero C; Maechler F; Fankhauser-Rodriguez C; Kola A; Schrenzel J; Harbarth S; Bonten M; Gastmeier P; Canton R; Ruiz-Garbajosa P;
    J Antimicrob Chemother; 2018 Nov; 73(11):2973-2980. PubMed ID: 30124851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region.
    Johnston BD; Thuras P; Porter SB; Castanheira M; Johnson JR
    J Glob Antimicrob Resist; 2021 Mar; 24():190-197. PubMed ID: 33460842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive Genetic Commonality among Wildlife, Wastewater, Community, and Nosocomial Isolates of Escherichia coli Sequence Type 131 (
    Jamborova I; Johnston BD; Papousek I; Kachlikova K; Micenkova L; Clabots C; Skalova A; Chudejova K; Dolejska M; Literak I; Johnson JR
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061277
    [No Abstract]   [Full Text] [Related]  

  • 14. Population snapshot of the extended-spectrum β-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital.
    Tóth K; Tóth Á; Kamotsay K; Németh V; Szabó D
    Ann Clin Microbiol Antimicrob; 2022 Feb; 21(1):3. PubMed ID: 35144632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of Escherichia coli sequence type 131 and its H30/H30-Rx subclones recovered from extra-intestinal infections: first report of OXA-48 producing ST131 clone from Iran.
    Hojabri Z; Mirmohammadkhani M; Kamali F; Ghassemi K; Taghavipour S; Pajand O
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1859-1866. PubMed ID: 28550370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Identification of Different Escherichia coli Sequence Type 131 Clades.
    Matsumura Y; Pitout JDD; Peirano G; DeVinney R; Noguchi T; Yamamoto M; Gomi R; Matsuda T; Nakano S; Nagao M; Tanaka M; Ichiyama S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584160
    [No Abstract]   [Full Text] [Related]  

  • 17. The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.
    Price LB; Johnson JR; Aziz M; Clabots C; Johnston B; Tchesnokova V; Nordstrom L; Billig M; Chattopadhyay S; Stegger M; Andersen PS; Pearson T; Riddell K; Rogers P; Scholes D; Kahl B; Keim P; Sokurenko EV
    mBio; 2013 Dec; 4(6):e00377-13. PubMed ID: 24345742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant.
    Demirci-Duarte S; Unalan-Altintop T; Eser OK; Cakar A; Altun B; Sancak B; Gur D
    Diagn Microbiol Infect Dis; 2020 Sep; 98(1):115098. PubMed ID: 32603974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum β-lactamase-producing Escherichia coli isolated from healthy humans in Mexico, including subclone ST131-B2-O25:H4-H30-Rx.
    Cortés-Cortés G; Lozano-Zarain P; Torres C; Alonso CA; Ríos-Torres AM; Castañeda M; López-Pliego L; Navarro A; Del Carmen Rocha-Gracia R
    J Glob Antimicrob Resist; 2017 Jun; 9():130-134. PubMed ID: 28552831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal/subclonal changes and accumulation of CTX-M-type β-lactamase genes in fluoroquinolone-resistant Escherichia coli ST131 and ST1193 strains isolated during the past 12 years, Japan.
    Fukushima Y; Sato T; Tsukamoto N; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
    J Glob Antimicrob Resist; 2021 Dec; 27():150-155. PubMed ID: 34509695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.